Literature DB >> 33111381

Design and analysis considerations for utilizing a mapping function in a small sample, sequential, multiple assignment, randomized trials with continuous outcomes.

Holly Hartman1, Roy N Tamura2, Matthew J Schipper1,3, Kelley M Kidwell1.   

Abstract

Small sample, sequential, multiple assignment, randomized trials (snSMARTs) are multistage trials with the overall goal of determining the best treatment after a fixed amount of time. In snSMART trials, patients are first randomized to one of three treatments and a binary (e.g. response/nonresponse) outcome is measured at the end of the first stage. Responders to first stage treatment continue their treatment. Nonresponders to first stage treatment are rerandomized to one of the remaining treatments. The same binary outcome is measured at the end of the first and second stages, and data from both stages are pooled together to find the best first stage treatment. However, in many settings the primary endpoint may be continuous, and dichotomizing this continuous variable may reduce statistical efficiency. In this article, we extend the snSMART design and methods to allow for continuous outcomes. Instead of requiring a binary outcome at the first stage for rerandomization, the probability of staying on the same treatment or switching treatment is a function of the first stage outcome. Rerandomization based on a mapping function of a continuous outcome allows for snSMART designs without requiring a binary outcome. We perform simulation studies to compare the proposed design with continuous outcomes to standard snSMART designs with binary outcomes. The proposed design results in more efficient treatment effect estimates and similar outcomes for trial patients.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian analysis; Binary outcome; Clinical trials; Patient reported outcomes; Rare disease; Small sample

Mesh:

Year:  2020        PMID: 33111381      PMCID: PMC9109654          DOI: 10.1002/sim.8776

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.497


  20 in total

Review 1.  The cost of dichotomising continuous variables.

Authors:  Douglas G Altman; Patrick Royston
Journal:  BMJ       Date:  2006-05-06

2.  Problems in dichotomizing continuous variables.

Authors:  D G Altman
Journal:  Am J Epidemiol       Date:  1994-02-15       Impact factor: 4.897

3.  Estimation of treatment effect for the sequential parallel design.

Authors:  Roy N Tamura; Xiaohong Huang; Dennis D Boos
Journal:  Stat Med       Date:  2011-12-05       Impact factor: 2.373

4.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

Authors:  J T Wei; R L Dunn; M S Litwin; H M Sandler; M G Sanda
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

5.  Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.

Authors:  Joanna C Robson; Jill Dawson; Helen Doll; Peter F Cronholm; Nataliya Milman; Katherine Kellom; Susan Ashdown; Ebony Easley; Don Gebhart; Georgia Lanier; John Mills; Jacqueline Peck; Raashid Ahmed Luqmani; Judy Shea; Gunnar Tomasson; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2018-04-25       Impact factor: 19.103

6.  Sample size determination for Bayesian analysis of small n sequential, multiple assignment, randomized trials (snSMARTs) with three agents.

Authors:  Boxian Wei; Thomas M Braun; Roy N Tamura; Kelley Kidwell
Journal:  J Biopharm Stat       Date:  2020-09-06       Impact factor: 1.051

7.  The patient's view on rare disease trial design - a qualitative study.

Authors:  C M W Gaasterland; M C Jansen- van der Weide; M J du Prie-Olthof; M Donk; M M Kaatee; R Kaczmarek; C Lavery; K Leeson-Beevers; N O'Neill; O Timmis; V van Nederveen; E Vroom; J H van der Lee
Journal:  Orphanet J Rare Dis       Date:  2019-02-07       Impact factor: 4.123

8.  Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone.

Authors:  Robert G Micheletti; Christian Pagnoux; Roy N Tamura; Peter C Grayson; Carol A McAlear; Renee Borchin; Jeffrey P Krischer; Peter A Merkel
Journal:  Trials       Date:  2020-04-28       Impact factor: 2.279

9.  A Bayesian analysis of small n sequential multiple assignment randomized trials (snSMARTs).

Authors:  Boxian Wei; Thomas M Braun; Roy N Tamura; Kelley M Kidwell
Journal:  Stat Med       Date:  2018-07-16       Impact factor: 2.373

Review 10.  Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.

Authors:  Ralf-Dieter Hilgers; Malgorzata Bogdan; Carl-Fredrik Burman; Holger Dette; Mats Karlsson; Franz König; Christoph Male; France Mentré; Geert Molenberghs; Stephen Senn
Journal:  Orphanet J Rare Dis       Date:  2018-05-11       Impact factor: 4.123

View more
  1 in total

Review 1.  Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.

Authors:  Kelley M Kidwell; Satrajit Roychoudhury; Barbara Wendelberger; John Scott; Tara Moroz; Shaoming Yin; Madhurima Majumder; John Zhong; Raymond A Huml; Veronica Miller
Journal:  Orphanet J Rare Dis       Date:  2022-05-07       Impact factor: 4.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.